Aptamer Group plc, a leading developer of next-generation synthetic binders, has made a significant breakthrough in its liver fibrosis treatment research. The companys innovative Optimer® platform has successfully identified and validated a novel molecular target for targeted gene therapy delivery to specific liver cells that drive scarring. This advance positions Aptamer for strategic licensing discussions with global pharmaceutical partners in the $20 billion fibrosis market.
The Optimer® technology acts as a magic bullet, precisely targeting a protein in scarred livers and delivering siRNA gene therapy to hepatic stellate cells (HSCs), which cause liver scarring. In laboratory <mark style="background-color:yellow">test</mark>s, the Optimer®-siRNA system significantly reduced processes that mimic scar tissue formation and slowed the harmful activity of HSCs.
Aptamers unique approach to target identification has led to the discovery of a specific protein marker for HSCs, setting their technology apart for precision medicine. The Optimer® platform is compatible with various RNA-based medicines, making it highly versatile.
The company is now planning outsourced in vivo studies to evaluate the platforms performance in animal models and is in discussions with major pharmaceutical companies for parallel studies. These efforts aim to confirm the efficacy and safety of the Optimer® platform, paving the way for human trials and strategic collaborations in the multi-billion-dollar fibrosis market.